Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2021 | Biomarkers in sickle cell disease

David Rees, MA, MBBS, FRCP, FRCPath, FRCPCH, King’s College Hospital, London, UK, discusses using biomarkers to predict outcomes in sickle cell disease (SCD), and suggests particular treatments. Using SCD biomarkers such as transcranial Doppler velocity measurements can effectively predict the risk of stroke in children. Despite various studies using SCD biomarkers as evidence to reveal the pathology of SCD, Prof. Rees outlines the limits of SCD biomarkers as a prognostic tool. This interview took place at the 2021 British Society for Haematology Annual Scientific Meeting.